Sanofi’s $2.2bn Dynavax deal — and the quiet power of adult vaccines
The pandemic made vaccines noisy. This acquisition is a bet
The anti-ageing bet on the liver: why longevity biotech’s first real drugs may start here
A new generation of biotech start-ups is trying to “rejuvenate”
From California to Manchester: How One Gene Therapy Is Rewriting Hunter Syndrome Care
When a three-year-old from California flies to Manchester for a
The patch that could unstick vaccination: Vaxxas’s A$90m bet on needle-free delivery
Brisbane-based Vaxxas has raised ~A$90m (A$49.22m Series D equity plus
From Hope to Proof: How Prasad’s FDA Could Reshape Biotech Approvals
When Dr. Vinay Prasad was abruptly removed from his FDA
More Than a Shot: Sanofi’s Vicebio Deal Shows the Power of Platform Biotech
In the high-stakes world of biotechnology, big pharma acquisitions often
From Crypto to Cytoplasm: Brian Armstrong’s NewLimit Targets Hepatocytes for Anti-Aging Breakthrough
In a biotech landscape often preoccupied with the elusive fountain
Beijing’s Biotech Blitz Is Outpacing America. Washington Needs a War Plan.
For decades, the United States has led the world in
A Champion Departs: Peter Marks’ Resignation and Biotech’s Crossroads
When Dr. Peter Marks walked out of the FDA’s headquarters
Syngene’s Baltimore Bet: Indian Biotech’s American Ambitions and Global Supply Shake-Up
A few years ago, Emergent BioSolutions’ Bayview plant in Baltimore
Unlocking New Frontiers: How Generative AI is Transforming Protein Design and Drug Discovery
Abstract This report explores the transformative impact of generative artificial
Orna Therapeutics Acquires ReNAgade Therapeutics to Enhance RNA Medicine Development
Orna Therapeutics, a Massachusetts-based biotech firm specializing in circular RNA
MOST POPULAR
